A Phase 1b, Multicenter, Open-label Study of ACP-196 in Combination with Bendamustine and Rituximab (BR) in Subjects with Mantle Cell Lymphoma
The goal of this clinical research study is to learn about the safety of acalabrutinib (ACP-196) in combination with rituximab and bendamustine. Researchers also want to learn if the study drug combination can help to control mantle cell lymphoma (MCL).
Treatment Location: N/A
IRB Review and Approval Date: 06/21/2016
Recruitment Status: Closed
Projected Accrual: N/A
Information and next steps
For general questions about clinical trials: